QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform
| ABX | ||
| 3,151.895 | ||
| 24.1390 | 0.0077% | |
| BISNIS-27 | ||
| 421.838 | ||
| 1.3930 | 0.0033% | |
| DBX | ||
| 2,877.851 | ||
| 24.9730 | 0.0088% | |
| ECONOMIC30 | ||
| 85.053 | ||
| 0.4180 | 0.0049% | |
| ESGQKEHATI | ||
| 102.677 | ||
| 0.3040 | 0.0030% | |
| ESGSKEHATI | ||
| 103.498 | ||
| 0.3050 | 0.0030% | |
| I-GRADE | ||
| 151.924 | ||
| 0.1310 | 0.0009% | |
| AUDRP | ||
| 12,473.810 | ||
| -2.5900 | -0.0208% | |
| EURRP | ||
| 20,114.890 | ||
| 17.2800 | 0.0860% | |
| JPYRP | ||
| 112.947 | ||
| -0.4482 | -0.3953% | |
| SINRP | ||
| 13,979.960 | ||
| -6.9200 | -0.0495% | |
| USDRP | ||
| 17,858.000 | ||
| -55.0000 | -0.3070% | |
